Investors Encouraged to Join Class Action Lawsuit
Bronstein, Gewirtz & Grossman, LLC, a prominent law firm, is advising investors about a newly filed class action lawsuit against Altimmune, Inc. (NASDAQ: ALT). This initiative aims to help those who suffered substantial financial losses while holding Altimmune securities.
Understanding the Class Definition
The class action lawsuit is structured to recover damages for individuals and entities that bought or acquired shares of Altimmune during the defined Class Period, specifically from August 10, 2023, to June 25, 2025. If you fall into this category, it is vital to take action.
How to Participate
Investors who meet the criteria for the class are urged to explore their options by visiting the law firm's official site. This move could potentially connect them with others in similar positions, amplifying their voices and claims in court.
Details of the Lawsuit
The complaint against Altimmune's executives highlights several critical allegations. It states that throughout the Class Period, several materially false and misleading statements were made. Particularly, the company misrepresented the prospects of its Pemvidutide trial results, leading to inflated expectations among investors.
Core Allegations of Misrepresentation
The key claims include accusations that the management failed to disclose important aspects of the IMPACT Phase 2b MASH trial, suggesting that the results would not meet the necessary statistical significance due to a flawed trial design. Furthermore, it was argued that the company presented overly optimistic timelines and outcomes related to the drug's efficacy.
What to Expect Moving Forward
As the class action lawsuit progresses, those wishing to stay informed on the proceedings can access the complete complaint through the law firm's resources. It's also crucial for affected parties to consider the timeline; they must express intent to be lead plaintiffs by October 6, 2025, if interested.
Support for Investors
Investors can be assured that there are no upfront costs involved in joining the class action. This means that any legal fees would only be collected if the case results in a financial recovery, making it a risk-free opportunity for potential claimants.
Why Choose Bronstein, Gewirtz & Grossman?
Bronstein, Gewirtz & Grossman, LLC has built a reputation for excellence in representing investors in Securities Fraud cases. Their extensive track record of recovering significant settlements reflects their commitment and expertise in advocating for investor rights.
Ways to Stay Updated
To stay informed about updates regarding this class action lawsuit, individuals can follow Bronstein, Gewirtz & Grossman on various social media platforms. This is an excellent way to keep abreast of any new developments or insights shared by the firm.
How to Reach Out
For more information or to discuss potential involvement in the class action lawsuit, investors can reach out directly:
Bronstein, Gewirtz & Grossman, LLC
Contact: Peretz Bronstein or Nathan Miller
Phone: 332-239-2660 | Email: info@bgandg.com
Frequently Asked Questions
What is the purpose of the class action lawsuit against Altimmune?
The lawsuit seeks to recover damages for investors who acquired Altimmune securities during the specified Class Period and suffered losses.
How can I determine if I am eligible to join the class action?
If you purchased Altimmune securities between August 10, 2023, and June 25, 2025, you may be eligible to join.
Is there a cost involved in participating in the lawsuit?
No, participating in the lawsuit does not require any out-of-pocket expenses upfront. Legal fees are contingent upon a successful recovery.
Who can I contact for more information about the lawsuit?
For inquiries, you can reach out to Peretz Bronstein or Nathan Miller by calling 332-239-2660.
What should I do if I want to become a lead plaintiff?
If you wish to become a lead plaintiff, you need to express your interest by October 6, 2025.
